Study title:
Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.Incidence of Viral and fungal
infections following busulfan-based
reduced-intensity versus
myeloablative conditioning in
pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow
Transplant. 2009 Dec;15(12):1587-95.Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.Incidence of Viral and fungal
infections following busulfan-based
reduced-intensity versus
myeloablative conditioning in
pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow
Transplant. 2009 Dec;15(12):1587-95.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Virus Diseases [C02]
|
Brands: Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: Foscarnet |
ATC code: |
Document link:
Satwani P et al 2009.pdf
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|